ClinicalTrials.gg
Not yet recruitingNCT06747416Updated Dec 24, 2024

KN057 Multiple Dose Study in Patients with Hemophilia a or Hemophilia B with or Without Inhibitors

A Phase 2 interventional study of KN057 in Hemophilia a and B, sponsored by Suzhou Alphamab Co., Ltd.. Not yet recruiting. Open to male participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-12-24.

Sponsored by Suzhou Alphamab Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
Male
01

Study summary

The goal of this clinical trial is to evaluate the safety and efficacy of KN057 in adult patients with severe Hemophilia A (coagulation factor FVIII activity \<1%) or moderate-to-severe Hemophilia B (FIX activity ≤2%). Participants will be administered subcutaneously with KN057 once a week for 20 weeks. KN057 works differently than factor replacement products and will work in the presence of inhibitors. The potential for once weekly subcutaneous administration provides better convenience and compliance.

02

Conditions studied

  • Hemophilia a and B

Browse trials for

03

In context

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

This study's planned enrollment of 24 is below the median of 30 across 499 interventional studies indexed under Hemophilia A.

Browse Hemophilia A studies →

Lead sponsor

Suzhou Alphamab Co., Ltd. is the lead sponsor of 10 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male, 18-70 years old (including thresholds), body weight ≥40 kg and \<30 kg/m\^2.
  2. Severe Hemophilia A or moderate-to-severe Hemophilia B (coagulation factor FVIII activity \<1% or FIX activity ≤2%).
  3. Have ≥ 6 treated bleeding episodes within 24 weeks prior to screening (spontaneous and/or traumatic, excluding bleeding episodes related to surgery or traumatic operation).
  4. Patients without inhibitors must meet the following criteria: FVIII or FIX inhibitor test is negative during the screening period. Use coagulation factor replacement therapy for no less than 100 exposure days before screening.
  5. Patients with inhibitors must meet the following criteria: FVIII or FIX inhibitor test is positive during the screening period. Inhibitors level with high titer positive (≥5 BU/ml) or current low titer positive (\<5 BU/ml) to FVIII or FIX replacement and with FVIII or FIX recovery \< 60% of expected within previous 12 months prior to screening.

Exclusion criteria

Exclusion Criteria:

  1. Those with serious or poorly controlled chronic diseases or obvious systemic diseases: such as cardiovascular system, respiratory system, endocrine and metabolic system, urinary system, digestive system, diseases, neurological diseases or psychiatric diseases, bacterial or viral infection, etc.; have previously received lipid-lowering therapy for hypertriglyceridemia or are currently receiving lipid-lowering therapy for hypertriglyceridemia.
  2. Have a history of other hereditary or acquired bleeding disorders other than Hemophilia A and Hemophilia B.
  3. Have symptoms and signs related to thromboembolic disease or are receiving thrombolytic/antithrombotic treatment; have a history of coronary atherosclerotic disease, arterial or venous thrombosis, or ischemic disease of important organs.
  4. Have high risk factors for thrombosis, including reduced activity of antithrombin III, protein S or protein C.
  5. When bleeding occurred in the past, rFVIIa was ineffective and (activated) prothrombin complex concentrate (PCC/aPCC) treatment must be used.
  6. Are undergoing or planning to undergo immune tolerance induction therapy.
  7. Regular use of immunomodulatory therapy, such as regular infusion of immune globulin or regular use of hormones, is required.
  8. Those with allergies; those who are allergic to test drugs/similar drugs or ; those with a history of multiple allergies (two categories or more); those with a history of specific reactions, such as being allergic to heparin or having experienced heparin-induced thrombocytopenia.
  9. Hematological abnormalities: count ≤ 100 × 10\^9 /L; \< 100g/L; fibrinogen level \< lower limit of normal (LLN); > 1.5 times (ULN).
  10. Abnormal liver and kidney function: and/or aspartate aminotransferase >3 times ULN; lactate dehydrogenase >1.5 times ULN; total >1.5 times ULN; serum creatinine, triglyceride > ULN; albumin \<0.8 times LLN.
  11. Chronic active /C virus (HBV/, HBV-DNA or HCV-RNA quantitative detection indicates viral activity); (HIV) antibody positive; syphilis antibody positive; Have received antiviral treatment (only for HBV, HCV, and HIV) in the past 3 month, or have plans to undergo antiviral treatment within 28 weeks after the first dose.
  12. Have had major surgery within the past 3 months (determined by the investigator), or have elective surgery planned within 28 weeks after the first dose.
  13. Due to treatment needs, anti-fibrinolytic or platelet function-affecting drugs need to be used within 5 days before administration or within 28 weeks after the first administration, including medicines, such as aspirin, COX-1 and non-selective non-steroidal anti-inflammatory drugs (NSAIDs, except for acetaminophen), traditional herbal medicine or health supplements at investigator's discretion.
  14. Participated in clinical trials related to coagulation factors and received drug treatment within the past 1 month; participated in any other drug clinical trials and received investigational drug treatment within the past 3 months.
  15. Have been vaccinated in the past month, or have a vaccination plan within 28 weeks after the first dose, including inactivated vaccine, , recombinant protein vaccine, recombinant adenovirus vaccine, RNA vaccine, DNA vaccine, etc.
  16. Subjects with fertile mates are unable to use effective during the study period and within 3 months after the last dose; effective contraceptive methods include: vasectomy, scientific use of male condoms, etc.
  17. Have had treatment of Emicizumab within 6 months prior to screening;
  18. Have had any prior treatment of genetic therapy for hemophilia.
  19. Those participants who drink heavily or are alcoholic within 24 weeks prior to screening or can't avoid heavy drinking during the trial. Heavy drinking means more than 7 units of alcohol per week, 1 unit=360ml of beer, or 45ml of liquor with 40% alc/vol, or 150ml of wine.
  20. Other factors that the investigator considers inappropriate for participation in this trial.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    KN057

    Drug: KN057

Interventions

  • DrugKN057

    KN057 will be administered subcutaneously once a week.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of treatment emergent adverse events(TEAEs)

    TEAEs are adverse events occurred following the start of treatment or adverse events increasing in severity during treatment.

    Time frame: Week 0 up to Week 26

  2. Number of participants with abnormal laboratory findings in Hematology

    Including white blood cells, red blood cells, lymphocyte count, neutrophil count, monocyte count, eosinophil count, basophil count, lymphocyte percentage, neutrophil percentage, monocyte percentage, eosinophil percentage, basophil percentage, hemoglobin, hematocrit, platelet count.

    Time frame: Week 0 up to Week 26

  3. Number of participants with abnormal laboratory findings in Coagulation Function

    Including prothrombin time (PT), international normalized ratio (INR), activated partial thrombin time (APTT), thrombin time (TT), fibrinogen (FBG/FIB), D-dimer (D-Di), fibrin(ogen) degradation product (FDP), antithrombin-Ⅲ (AT-Ⅲ)

    Time frame: Week 0 up to Week 26

  4. Number of participants with abnormal laboratory findings in Blood Biochemistry

    Including total bilirubin (TBIL), indirect bilirubin (IBIL), direct bilirubin (DBIL), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (GGT), alkaline phosphatase (ALP), total protein (TP), albumin (ALB), globulin, white globulin ratio , urea and/or urea nitrogen (BUN) (collected according to the specific test item at the clinical site), creatinine (Cr), uric acid, glucose, total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL), high-density lipoprotein (HDL), lactate dehydrogenase (LDH), creatine kinase, sodium , potassium, chloride, calcium, C- reactive protein.

    Time frame: Week 0 up to Week 26

  5. Number of participants with clinically significant changes in 12-lead electrocardiograms

    Time frame: Week 0 up to Week 26

  6. Number of participants with clinically significant changes in vital signs

    Heart Rate, Respirations, Temperature, Blood Pressure

    Time frame: Week 0 up to Week 26

  7. Number of participants with clinically significant changes in physical examination Findings

    Time frame: Week 0 up to Week 26

  8. Incidence and severity of injection site reaction

    Time frame: Week 0 up to Week 26

Secondary outcomes

  1. Plasma Concentration of KN057

    Time frame: Week 0 up to Week 26

  2. Maximum Plasma Concentration (Cmax) of KN057

    Time frame: Week 0 up to Week 26

  3. Time to Reach Maximum Plasma Concentration (Tmax) of KN057

    Time frame: Week 0 up to Week 26

  4. Maximum observed KN057 concentration at steady-state

    Time frame: Week 0 up to Week 26

  5. Area Under the Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of KN057

    Time frame: Week 0 up to Week 26

  6. Apparent Clearance (CL/F) of KN057

    Time frame: Week 0 up to Week 26

  7. Changes of Free Tissue factor pathway inhibitor (TFPI) from baseline

    Tissue factor pathway inhibitor (TFPI) is an anticoagulant protein that inhibits early phases of the procoagulant response.

    Time frame: Week 0 up to Week 26

  8. Changes of Total TFPI from baseline

    TFPI: Tissue factor pathway inhibitor

    Time frame: Week 0 up to Week 26

  9. Changes of Prothrombin fragment 1+2 (PF1+2) from baseline

    Time frame: Week 0 up to Week 26

  10. The number and proportion of participants who produce anti-KN057 antibody

    Time frame: Week 0 up to Week 26

  11. The number and proportion of participants who produce anti-KN057 neutralizing antibodies

    Time frame: Week 0 up to Week 26

  12. Annualized Bleeding Rate (ABR)

    ABR=number of bleeding episodes reported in visit days÷visit days×365.25

    Time frame: Week 0 up to Week 20

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Sep 2026, 12 months later.

Of 18 phase 2 interventional studies under Hemophilia A, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 20. This study's planned 12 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2024
First posted
Dec 24, 2024
StartEst.
Sep 2, 2025
Primary completionEst.
Sep 2, 2026
CompletionEst.
Dec 31, 2026
Last update
Dec 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06747416
Lead sponsor
Suzhou Alphamab Co., Ltd.
Responsible party
Sponsor
First posted
Dec 24, 2024
Start date
Sep 2, 2025 (estimated)
Primary completion
Sep 2, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Dec 24, 2024

Study contacts

Yanrong Dong Master
Contact
yanrongdong@alphamab.com
+86 18914005458

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KN057

Start the discussion